Patients chronically infected with hepatitis C virus (HCV) are at risk of developing end-stage liver disease and hepatocellular carcinoma. Development of drugs to inhibit hepatocyte damage and a vaccine against HCV is hampered by the lack of a small animal model. We generated mice in which the viral genome RNA was always present in the hepatocytes using a special transgene.
(FCS). The HCV-containing fractions of sucrose density gradient or the sera from transgenic mice were inoculated to culture cells, incubated for 3 h and cultured for a further 2 days with complete media at 37 0 C in a CO 2 incubator. The cells were fixed with 3.5% formalin in phosphate-buffered saline (PBS), and permeabilised with 0.2% Triton X-100 in PBS. Cells were incubated with rabbit HCV-Core antibody (Abbiotec, San Diego, CA, USA), followed by an incubation with Alexa 647-conjugated goat anti-rabbit IgG secondary antibody (Invitrogen, Carlsbad, CA, USA). The cells were then rinsed with PBS and counter-stained with DAPI (Dojindo Molecular Technologies, Inc., Japan). The washed cells were observed with a confocal microscope FV-1000 (Olympus, Tokyo, Japan).
Immunohistochemistry and determination of the HCV genome RNA copy. Liver tissues were excised from 6 and 12-month-old wild type and transgenic mice, and fixed in 10% formalin in PBS overnight for haematoxylin and eosin staining (Sigma-Aldrich) and frozen in OCT compound (Tissue Tech, Torrance, CA, USA) for Oil Red O staining (Sigma-Aldrich). All histological staining was performed in accordance with conventional procedures. The liver and other tissues (spleen, kidney and heart) were also frozen in OCT compound for HCV-Core antibody staining. The frozen sections (4 µm thickness) were prepared and incubated with rabbit HCV-Core antibody at room temperature for 1 h, followed by a further incubation with Alexa 647-conjugated anti-rabbit IgG secondary antibody. The sections were then rinsed with PBS and counter-stained with DAPI, and observed with a confocal microscope FV-1000.
Total RNA was isolated from each tissue as described previously (8) . Briefly, the liver (about 1 g) or other tissues were excised from a mouse, put in liquid nitrogen, and cut into pieces. The tissue pieces were homogenized in guanidinium thiocyanate/Tris/EDTA/-mercaptoethanol solution with Polytoron (PT 3100, KIMEMATIKA, Switzerland) and the supernatant layered onto a 5.7 M CsCl solution. Following centrifugation, using a SW41 rotor (Beckman) for 12 h at 27,000 rpm, the RNA pellet was washed once with 70% ethanol and dissolved in H 2 O. The HCV RNA from each serum was purified using a QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germany) according to the supplier's protocol. The RNA copy numbers of the HCV genome from the tissues and sera were determined as described previously (27) . Briefly, RNA samples were subjected to real-time detection (RTD)-PCR (TaqMan, Roche, USA) and the copy numbers of the HCV RNA were determined using the Step One Plus RT-PCR system (Applied Biosystems, Bedford, MA, USA). In this system, one set of PCR primers (sense: 5'-CGGGAGAGCCATAGTGG-3' and anti-sense: 5'-AGTACCACAAGGCCTTTCG-3') and a probe (5'-CTGCGGAACCGGTGAGTACAC-[TAMRA]-3') targeting the 5ʹ non-coding region (UTR) of HCV were used. A standard curve was constructed using a ten-fold dilution series (10 1 -10 7 copies) of in vitro-transcribed and previously titrated synthetic HCV RNA. In this system, the detection limit was ten copies per reaction.
For determination of the HCV genome RNA replication, 40 μg of the HCV NS5A inhibitor, BMS-790052 (Selleck Chemicals, Houston, TX, USA) per mouse was delivered by intraperitoneal injection. Blood was collected at 0 and 24 h after drug administration from mock, vehicle (2%DMSO/PBS) and drug-treated mice, and the HCV RNA copy numbers were determined from the collected sera by RTD-PCR, as mentioned above.
ALT and AST measurements of the sera. The ALT and AST activities in the sera were measured using an alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity assay kits (BioVision, Milpitas, CA, USA).
Sucrose density gradient analysis of the virus. The sera after RNaseA treatment (Fig. 3A) , or seven-fold concentrated sera (Fig. 3C ) (500 µL) from transgenic A line mice, were layered onto a continuous 20-60% (wt/vol) sucrose gradient in PBS and centrifuged at 35,000 rpm at 4 ºC for 16 h using a SW41 rotor (Beckman-Coulter). Fractions (1.1 mL each) were collected from the top of the tube (ten fractions in total) and the density for each fraction was determined. The copy number of the HCV RNA and the infectious titre were determined from each fraction as described above and below, respectively.
Infectious titre of HCV in sera. The infectivity titre of the sera was determined on Huh7. 
RESULTS

Creation of a transgenic mouse containing full-length HCV genome, which produces infectious virus in vivo
RNA polymerase I (Pol I) is a cellular enzyme that transcribes pre-rRNA without the addition of either a 5ʹ cap structure or a 3ʹ poly (A) tail and has previously been used to make influenza virus (20) and HCV (15) . Thus, in this study we used a human pre-rRNA (Pol I) promoter to direct expression of the whole HCV genome cDNA (JFH1 strain) in mice. The human Pol I promoter-HCV genome cDNA-mouse Pol I terminator construct (15) flanked with Swa I sites (Fig. 1A) , was injected into fertilised mice eggs to generate transgenic mice containing full-length HCV genome. Sixty four mice were generated and among them, seventeen were positive for HCV transgene confirmed by polymerase chain reaction (PCR) analysis. We further confirmed the presence of transgene in seventeen founder mice by southern blot analysis (Data not shown).
Initially, we determined the transgene copy numbers in 17 transgenic mice, named A line through to Q line. Among these 17 lines, we maintained five mice lines (Table 1) The A line produced ~ 3 × 10 4 copies per μg total liver RNA and ~ 3 × 10 6 copies per mL sera.
The HCV RNA levels in the A line mice were comparable to that recorded in patients with chronic HCV infection. The B line produced slightly less titre, while the D line and the J line produced about 1/25th and 1/75th of the A line, respectively (Table 1) . Next, the numbers of HCV RNA copies were measured in various tissues of both the A and B line mice and found to be specifically expressed in the liver, spleen, kidney, lung, testis and heart (Fig. 1D ).
Immunohistochemical staining showed conclusively that the liver of transgenic A line mice was strongly positive for the HCV-Core antibody (Fig. 1E ). Other tissues were also positive for the antibody, but the fluorescence intensities were proportional to the HCV RNA copy number (Fig. 2 ). The differences in RNA copy numbers is likely due to the absence or low expression of miR122, which stabilises the HCV RNA in tissues other than the liver (7, 26) . As the apoE protein is an essential factor for the production of HCV particles, only the liver is expected to produce an infectious virus via the apoE protein (2, 7, 13, 26) .
Replication of the transcribed HCV genome RNA
Next, we characterised the virus particles in sera of A line mice. Sucrose density gradient analysis showed the density of the peak fraction of HCV RNA to be 1.17 g/mL, even after
RNaseA treatment (Fig. 3A) . The infectivity of the virus was checked using Huh7.5.1 hepatoma cells. Cytoplasmic staining was strongly positive for the HCV-Core antibody (Fig. 3B) . The infectious titre from each fraction of the sucrose density gradient of seven-fold concentrated sera obtained from A line mice was determined (Fig. 3C) . The peak of infectivity exhibited at a density of 1.12 g/mL that was slightly lower than that of the HCV RNA peak. The HCV RNA copies in sera were compared with the infectious titre and it was found that the specific infectivity was approximately 2 × 10 -4 focus-forming units (FFU)/RNA copy (Table 2) .
Furthermore, we investigated whether the HCV genome RNA, which was transcribed by Pol I, could replicate. After injecting a HCV NS5A inhibitor, BMS-790052, the HCV RNA copy numbers were found to decrease to one-third in both the liver and sera of transgenic A line mice after 24 h (Fig. 3D and 3E ). We therefore concluded that the transcribed HCV genome RNA could replicate and produce infectious viruses.
Pathological changes in the transgenic A line mice
Finally, we observed the pathological changes in the A line mice. Haematoxylin and eosin staining showed no infiltration of the inflammatory immune cells and no gross disarrangement of the hepatic acini. In contrast to wild type mice, many hepatocytes containing vacuoles were observed in 6 and 12 month old transgenic mice (Fig. 4A-4D ), and lipid storage in vacuoles of hepatocytes was observed. These vacuolating lesions appeared in the cytoplasm of hepatocytes of transgenic A line mice and were stained positive by Oil Red O (Fig. 4E-4H ). It indicated that these lesions are steatosis, and steatosis became severity with the increasing age of the transgenic mice ( Fig. 4E-4H ). In contrast, no steatosis was observed in the livers of wild type mice. In addition, we observed that four 15-month-old mice of transgenic A line were free of hepatocellular carcinoma (data not shown). Furthermore, we measured changes in levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzymes, which are indicators of hepatocyte damage, and found no increases ( (14) . In all such transgenic mice no viral particles were produced since their transgenes did not contain complete 5ʹ and 3ʹ UTRs. However, in this study we used Pol I promoter first time for producing HCV in vivo and succeeded to produce infectious virus in transgenic mice. In addition, our transgenic mice developed severe hepatic steatosis at the age of 6 months, which is one of the characteristic features of chronic HCV infection. As shown in Fig. 1E , the core protein is present in large amounts in all hepatocytes. We expect that other structural and non-structural proteins of HCV were also present in these hepatocytes. As shown in Fig. 3D and 3E, one-third of the genome RNA was synthesised by Pol I polymerase, while the other two-thirds were synthesised by replication (viral RNA-dependent RNA polymerase). From this result, we concluded that HCV RNA is being replicated in our transgenic mice.
Our transgenic mice were immunotolerant to HCV. The hepatocytes that mimic the post-entry state of HCV infection were not destroyed by immune reaction and the ALT and AST levels in sera did not increase (Table 3) . In this study, the mice with a high copy number of transgene produce sufficiently high titres of infectious viruses, compared to the patients with chronic HCV infection. In the liver of our A line mouse, transcribed HCV RNA could undergo polyprotein processing, genome RNA replication and virus assembly, in a manner similar to that reported for HCV in infection of human hepatocytes. Unlike immortalised hepatocytes or primary hepatocytes that generally tend to lower expression of miR122, and apoE (7, 26) and P450 Cyp proteins over time, the protein levels of the A line mouse are extremely high and provide this mouse line a fully differentiated state in which we can study potential drug treatments for HCV.
Moreover, these high levels of proteins should support better analysis and detection methods to further study the molecular mechanisms of polyprotein processing, genome RNA replication and viral assembly. Furthermore, since the A line mouse clearly showed steatosis, which is evidence of metabolic abnormality in HCV infections, this model could also be used to investigate dysregulation of metabolism and signal transduction in infected hepatocytes.
Significantly, when whole-genome cDNAs for wild type 1a, 1b and 2b substrains were replaced in the JFH1 (2a substrain) cDNA position of the transgene, a large amount of the infectious virus of each HCV substrain would be produced in the mice, which cannot be achieved using hepatoma cell culture lines. Consequently, our transgenic mouse could provide a good model system to study potential drug treatments against the different HCV infections in humans.
Last but not least, the application of this system to other animals, including cattle and horses, could produce an extremely large amount of virus, which would be useful for vaccine development. FFU, focus forming unit. Values are expressed as mean ± S.D. from three individual mice for each group. 
